Trial Profile
Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 4166 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme
- 12 Dec 2020 Results published in the Clinical Cancer Research
- 29 Oct 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology